BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25015857)

  • 1. Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas.
    Mohanty SK; Smith SC; Chang E; Luthringer DJ; Gown AM; Aron M; Amin MB
    Am J Clin Pathol; 2014 Aug; 142(2):173-83. PubMed ID: 25015857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
    Kunju LP; Mehra R; Snyder M; Shah RB
    Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma.
    Downes MR; Torlakovic EE; Aldaoud N; Zlotta AR; Evans AJ; van der Kwast TH
    J Clin Pathol; 2013 Sep; 66(9):779-86. PubMed ID: 23775437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
    Epstein JI; Egevad L; Humphrey PA; Montironi R;
    Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
    Gordetsky J; Epstein JI
    Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: a diagnostic dilemma with immunohistochemical evaluation of 2 cases.
    Martínez-Rodríguez M; Ramos D; Soriano P; Subramaniam M; Navarro S; Llombart-Bosch A
    Int J Surg Pathol; 2007 Apr; 15(2):213-8. PubMed ID: 17478786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer.
    Chan E; Garg K; Stohr BA
    Mod Pathol; 2020 Sep; 33(9):1802-1810. PubMed ID: 32313185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
    Lane Z; Hansel DE; Epstein JI
    Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
    Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
    Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma.
    Bassily NH; Vallorosi CJ; Akdas G; Montie JE; Rubin MA
    Am J Clin Pathol; 2000 Mar; 113(3):383-8. PubMed ID: 10705819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.
    Gruver AM; Amin MB; Luthringer DJ; Westfall D; Arora K; Farver CF; Osunkoya AO; McKenney JK; Hansel DE
    Arch Pathol Lab Med; 2012 Nov; 136(11):1339-46. PubMed ID: 23106579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma.
    Ch'ng ES
    Sci Rep; 2021 Mar; 11(1):6765. PubMed ID: 33762601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma.
    Mhawech P; Uchida T; Pelte MF
    Hum Pathol; 2002 Nov; 33(11):1136-40. PubMed ID: 12454820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma.
    Oh WJ; Chung AM; Kim JS; Han JH; Hong SH; Lee JY; Choi YJ
    J Pathol Transl Med; 2016 Sep; 50(5):345-54. PubMed ID: 27498545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder.
    Paner GP; Annaiah C; Gulmann C; Rao P; Ro JY; Hansel DE; Shen SS; Lopez-Beltran A; Aron M; Luthringer DJ; De Peralta-Venturina M; Cho Y; Amin MB
    Hum Pathol; 2014 Jul; 45(7):1473-82. PubMed ID: 24780825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
    Genega EM; Hutchinson B; Reuter VE; Gaudin PB
    Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of p63 and high molecular weight cytokeratin in the distinction between urothelial carcinoma with prostatic stromal invasion and urothelial carcinoma with colonisation of prostatic ducts and acini.
    Chastain EC; Oliva IV; Osunkoya AO
    Pathology; 2012 Apr; 44(3):199-203. PubMed ID: 22406481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas.
    Liu H; Shi J; Wilkerson ML; Lin F
    Am J Clin Pathol; 2012 Jul; 138(1):57-64. PubMed ID: 22706858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
    Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
    Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.